These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36399020)

  • 1. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
    Iwata N; Nishimura K; Hara R; Imagawa T; Shimizu M; Tomiita M; Umebayashi H; Takei S; Seko N; Wakabayashi R; Yokota S
    Mod Rheumatol; 2023 Nov; 33(6):1162-1170. PubMed ID: 36399020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K; Hara R; Umebayashi H; Takei S; Iwata N; Imagawa T; Shimizu M; Tomiita M; Seko N; Kitawaki T; Yokota S
    Mod Rheumatol; 2021 Jan; 31(1):226-234. PubMed ID: 32552266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
    Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ;
    Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
    Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
    Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
    Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
    Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
    Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
    Quartier P; Alexeeva E; Constantin T; Chasnyk V; Wulffraat N; Palmblad K; Wouters C; I Brunner H; Marzan K; Schneider R; Horneff G; Martini A; Anton J; Wei X; Slade A; Ruperto N; Abrams K;
    Arthritis Rheumatol; 2021 Feb; 73(2):336-346. PubMed ID: 32783351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
    Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
    Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
    N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
    Alexeeva E; Krekhova E; Dvoryakovskaya T; Isaeva K; Chomakhidze A; Chistyakova E; Lomakina O; Denisova R; Mamutova A; Fetisova A; Gautier M; Vankova D; Kriulin I; Saygitov R
    Front Pediatr; 2023; 11():1114207. PubMed ID: 36911042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
    Brachat AH; Grom AA; Wulffraat N; Brunner HI; Quartier P; Brik R; McCann L; Ozdogan H; Rutkowska-Sak L; Schneider R; Gerloni V; Harel L; Terreri M; Houghton K; Joos R; Kingsbury D; Lopez-Benitez JM; Bek S; Schumacher M; Valentin MA; Gram H; Abrams K; Martini A; Lovell DJ; Nirmala NR; Ruperto N;
    Arthritis Res Ther; 2017 Jan; 19(1):13. PubMed ID: 28115015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Orrock JE; Ilowite NT
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.